HOME >> MEDICINE >> NEWS
Neoadjuvant and adjuvant systemic therapy for breast cancer give equivalent survival, study finds

The timing of systemic therapy--chemotherapy or endocrine therapy--for breast cancer does not appear to affect survival or disease progression. However, women who receive systemic therapy and radiation therapy without surgery may be more likely to experience a recurrence of their cancer compared with women treated with chemotherapy later, according to a new study in the February 2 issue of the Journal of the National Cancer Institute.

Neoadjuvant--also called preoperative or primary--systemic therapy for breast cancer may result in local tumor regression or even in a complete tumor response and may lead to a more limited extent of surgery--from radical mastectomy to some type of breast-conserving surgery--without risking patient survival. For these reasons, interest in the use of neoadjuvant therapy has been increasing.

To investigate how the timing of systemic therapy affects breast cancer outcomes, John P.A. Ioannidis, M.D., of the University of Ioannina School of Medicine in Greece, and colleagues performed a meta-analysis of nine randomized trials that had included nearly 4,000 breast cancer patients. The patients had been treated with systemic therapy either before or after surgery and/or radiation therapy.

There was no difference between neoadjuvant and adjuvant systemic therapy in terms of death, disease progression, or distant disease recurrence. However, neoadjuvant therapy was associated with a 22% increased risk of loco-regional disease recurrence compared with adjuvant therapy. This risk was higher (53%) when radiation therapy was used without surgery.

"[T]his meta-analysis demonstrates the equivalence of neoadjuvant and adjuvant treatments for breast cancer in terms of survival, disease progression, and distant recurrence and shows that an increased risk of loco-regional disease recurrence is associated with neoadjuvant treatment, especially when primary systemic treatment is not accompanied by any surgical interve
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
1-Feb-2005


Page: 1 2

Related medicine news :

1. MRI better than current standard in assessing neoadjuvant chemotherapy for breast cancer
2. Updated adjuvant data presented at SABCS show 30 percent reduction in recurrence
3. Different methods of adjuvant chemotherapy for colorectal cancer have similar outcomes
4. Study supports tailoring adjuvant therapy for early-stage breast cancer
5. Nordic collaboration gives new insights into adjuvant chemotherapy
6. Tumor-targeted immune cells cure prostate cancer in mice without causing systemic immune suppression
7. A blood test may reveal systemic factors that relate to periodontal disease, especially in men
8. Important information to consider about non-systemic cholesterol lowering agents
9. Study shows patch therapy may be as effective as oral medications
10. Novel therapy tested in mice could chase away cat allergies
11. Drug therapy may be comparable to invasive cardiac procedures for elderly patients with heart attack

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/27/2017)... (PRWEB) , ... July 27, 2017 , ... ... Barack Obama from 2012-2016, will keynote Day 2 of the HIMSS Healthcare Security ... kicks off at the Sheraton Boston Hotel, Sept. 11-13, 2017. , Daniel will ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: ... a major advancement in drug therapy for patients living with relapsing and primary ... a novel B cell targeted therapy that has been proven to significantly reduce ...
(Date:7/26/2017)... Yorba Linda, Ca (PRWEB) , ... July 26, 2017 , ... ... of optimize lyophilization processes. Inconsistent results freeze drying samples and a lengthy freeze dry ... , This webinar will discuss freeze drying techniques, as well as new accessories and ...
(Date:7/26/2017)... Maryland (PRWEB) , ... July ... ... Society for Pharmaceutical Engineering (ISPE) will host its 2017 Process Validation ... These concurrent events offer comprehensive solutions to process validation lifecycle challenges faced ...
(Date:7/26/2017)... ... 26, 2017 , ... Team Type 1 Foundation, a nonprofit organization pursuing a ... diabetes, is excited to announce the 106 college athletes with type 1 diabetes who ... 2005, the Team Type 1 Foundation has bestowed a total of 271 college scholarships ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... 13, 2017  Centurion Medical Products, a leader in medical product ... fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part ... alleviate patient pain while preventing unneeded emergency department admission due to ...
(Date:7/11/2017)... 11, 2017 Zymo Research Corp., also known as ,The Epigenetics ... biological aging in a precise manner using the myDNAge ™ test. ... a professor of human genetics and biostatistics at the David Geffen ... Health , Zymo Research,s proprietary DNAge ™ technology is used to ... ...
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... has agreed to schedule an End-of-Phase II meeting with ... its oral insulin capsule ORMD-0801 in the treatment of ... and secondary endpoints by indicating a statistically significant lowering ...
Breaking Medicine Technology:
Cached News: